Investment Rating - The report maintains an "Outperform" rating for the light industry manufacturing sector [3] Core Insights - The sentiment in the real estate chain continues to improve, leading to a significant recovery in the valuations of leading home furnishing companies. Recommendations include Gujia Home, Oppein Home, and others, while also monitoring undervalued companies like Minhua Holdings and Zhibang Home [2] - Suzano, a Brazilian company, plans to increase the price of hardwood pulp by $10 per ton starting in February, which is expected to support paper prices. Continued recommendations include Sun Paper and attention to Jiulong Paper and Bohui Paper [2] Summary by Sections Home Furnishing - The home furnishing sector is experiencing a valuation recovery due to improved policy expectations and a rebound in second-hand housing transactions. In 2025, Shanghai's second-hand home transactions reached 254,000 units, the highest in four years, indicating a marginal improvement in supply-demand dynamics [6][12] - The sector's valuation and institutional holdings are at historical lows, suggesting a potential for short-term recovery in valuations [6] Paper Industry - As of January 30, 2026, the prices for various paper types remained stable, with double glue paper at 4725 CNY/ton, copper plate paper at 4660 CNY/ton, and white card paper at 4269 CNY/ton. However, box board paper saw a slight decrease to 3517.2 CNY/ton, while corrugated paper increased to 2676.25 CNY/ton [6][53] - The paper industry is expected to benefit from the price increase in hardwood pulp, with a projected rise of $10 per ton in Asian markets [6] Packaging - Xianggang Technology forecasts a net profit of 100 million to 138 million CNY for the year, representing a year-on-year increase of 52.14% to 109.95% [6] - The company has received global certification for its PHA film products, enhancing its market position [6] Export Chain - The export chain is facing pressure due to the depreciation of the dollar and high performance baselines from the previous year. However, there is potential for recovery as U.S. interest rates decrease and real estate sales improve [6] Light Industry Consumption - Zhongshun Jierou expects a net profit of 300 million to 330 million CNY for 2025, a year-on-year increase of 289% to 328%, driven by lower raw material costs and improved operational efficiency [6] - Recommendations include focusing on dental care leader Dengkang Oral and medical products driven by high growth in cotton soft towels and sanitary napkins [6] New Tobacco Products - Altria reported a net revenue of $23.279 billion for 2025, a decrease of 3.1%, primarily due to significant non-cash impairment charges in its e-cigarette business [6] Textile and Apparel - Huafu Fashion anticipates a net profit of 55 million to 75 million CNY for 2025, with a year-on-year growth of 126.47% to 136.10% [6]

Summary of Key Points from the Conference Call Industry Overview - The overall positioning of the pharmaceutical industry in 2026 is "innovation first, with drugs and devices flying together," indicating a more diversified market compared to 2025 [2] - The investment in innovative drugs requires careful selection, with the current market conditions presenting a good opportunity for entry after adjustments at the beginning of the year [3] Company Insights - Biofarma companies are highlighted as better investment choices due to their combination of R&D innovation, certainty, and long-term growth potential. The record-breaking BD amount in 2025 indicates a positive cycle of capital inflow into R&D [6] - Companies like 康方 (Kangfang), 百济神州 (BeiGene), and 英恩生物 (InnoCare) are expected to achieve commercial breakthroughs or expand internationally in the coming years [20] Market Trends - The global innovative drug development cycle is just beginning, with Chinese companies expected to account for 40% of transaction amounts by 2025, indicating a strong role in the global market [5] - The second-generation immune checkpoint inhibitors (IO) market is projected to reach $120 billion within the next decade, with significant participation from Chinese innovative drugs [12] Technological Advancements - Emerging technologies such as small nucleic acid therapies, molecular glue, gene editing, and long-acting drugs are expected to see significant development in 2026 [11][18] - Dual-specific antibodies and antibody-drug conjugates (ADC) are highlighted as promising treatment options for various cancers, including triple-negative breast cancer and small cell lung cancer [16][14] Policy and Regulatory Environment - The Chinese healthcare negotiation supports emerging therapies, including ADCs and siRNA, which are included in the healthcare directory, promoting self-sustaining funding and attracting more investors [7] Investment Opportunities - The report emphasizes the importance of focusing on companies with clear growth potential and stable revenue expectations, particularly those with significant upcoming data releases [26] - Notable companies to watch include 康诺亚 (Conway), 康弘 (Kanghong), and 毕比特 (BIBIT), which are considered to have strong upside potential [24] Conclusion - The future growth of companies in the pharmaceutical sector will rely on their global ecosystem platforms and the continuous iteration of their pipeline priorities, with a focus on high-potential projects [22]

Group 1 - Smoore International (06969.HK) experienced a rebound of over 6% [2] - As of the report, the stock rose by 5.54%, reaching HKD 11.44 [2] - The trading volume amounted to HKD 294 million [2]

Core Viewpoint - The recent adjustment in the electronic cigarette export tax rebate policy is expected to significantly impact the electronic cigarette manufacturing industry, leading to a new round of industry reshuffling. Although the short-term performance of Smoore International (06969) may be affected, its long-term position is likely to be further solidified [1] Group 1: Company Insights - Smoore International's stock rebounded over 6%, currently trading at 11.44 HKD with a transaction volume of 294 million HKD [1] - The company is closely tied to leading brands, which may help it navigate the short-term challenges posed by the tax rebate policy [1] Group 2: Industry Analysis - The adjustment in tax rebates is anticipated to help the industry gradually emerge from the price war [1] - International tobacco giants are entering mainstream markets with HNB products, which may boost sales of new tobacco products in new regions [1] - There is potential for increased profitability in regions like the UK and Europe, particularly with the shift towards more profitable pod-based and open-system products [1] - Strengthened enforcement of electronic cigarette regulations in the U.S. is expected to create significant recovery space for compliant product shares [1]

Group 1 - The core viewpoint of the article highlights a significant rebound in Smoore International's stock price, which increased by over 6% and is currently trading at 11.44 HKD with a transaction volume of 294 million HKD [1] - The recent adjustment in the electronic cigarette export tax rebate policy is expected to have a substantial impact on the electronic cigarette manufacturing industry, leading to a new round of industry reshuffling [1] - Although Smoore's short-term performance may be affected by the tax rebate policy changes, its long-term position is anticipated to strengthen due to its deep ties with leading brands [1] Group 2 - The reduction in tax rebate incentives is expected to help the industry gradually emerge from the price war [1] - With the entry of international tobacco giants' HNB products into mainstream markets, the sales of the company's new tobacco products in new regions are likely to contribute to incremental growth [1] - The enforcement of electronic cigarette regulations, particularly in the United States, is expected to create significant recovery opportunities for compliant product market share [1]

Group 1 - The company conducted significant share buybacks on December 11 and 12, totaling nearly 200 million HKD, reflecting management's long-term confidence in the company's value and future growth [1] - On December 11, the company repurchased 8.14 million shares at an average price of 12.26 HKD per share, costing 99.77 million HKD, and on December 12, it repurchased 7.99 million shares at an average price of 12.48 HKD per share, costing 99.76 million HKD [1] - The proportion of shares held by the trustee increased from 1.2853% to 1.5457% following these buybacks [1] Group 2 - In Q3 2025, the company's revenue reached approximately 4.197 billion RMB, a year-on-year increase of 27.2%, driven by the successful launch of heated non-combustible (HNB) products in major global markets [1] - The company benefited from stricter global regulations leading to the elimination of non-compliant products, positioning itself as a compliant leader in the industry [1] - Adjusted net profit for Q3 was approximately 444 million RMB, reflecting a year-on-year growth of 4.0%, with effective cost control as the growth rate of expenses was lower than that of revenue [1] Group 3 - The company is recognized as a global leader in electronic vaporization, focusing on R&D and technological leadership [2] - Future revenue projections for the company are 14.108 billion RMB, 16.717 billion RMB, and 19.867 billion RMB for 2025-2027, with year-on-year growth rates of 19.57%, 18.50%, and 18.84% respectively [2] - Net profit forecasts for the same period are 1.043 billion RMB, 1.931 billion RMB, and 2.726 billion RMB, with growth rates of -19.93%, 85.12%, and 41.14% respectively [2]

Investment Rating - The report maintains a "Recommended" rating for the light industry manufacturing sector [2] Core Insights - Real estate data remains under pressure, but national subsidies and the expansion of the trade-in policy are driving a recovery in consumption. In 2025, the cumulative sales area of commercial housing in China reached 881.01 million square meters, down 8.7% year-on-year, while the cumulative sales amount reached 8393.68 billion yuan, down 12.6% year-on-year. The number of transactions in 30 major cities increased by 50% year-on-year, with a transaction area growth of 38% [1][11] - The implementation of a 62.5 billion yuan national subsidy on January 1 has led to a rapid qualification exhaustion, and the trade-in policy now includes smart and elderly-friendly home products. Major companies like Mousse, Oppein, and Youban are exploring strategic development and transformation in the competitive stock market [1][69] Summary by Sections Industry Key Data Tracking - **Home Furnishing**: Real estate data remains under pressure, but the return of national subsidies is expected to boost downstream demand recovery [7] - **Packaging**: Stable downstream demand and continuous optimization of the competitive landscape [52] Industry News and Dynamics - **Home Furnishing**: Policies are driving a recovery in consumption, with leading home furnishing companies pushing for strategic transformation [69] - **Packaging**: Anti-involution measures are improving corporate difficulties, and digitalization is driving industry upgrades [70] Light Industry Performance in Capital Markets - **Industry Yield Performance**: From December 2025 to January 2026, the CSI 300 index rose by 1.66%, while the light industry manufacturing sector increased by 5.10%, ranking 19th among 31 sub-industries [73] - **Industry Valuation**: The valuation of the sector has slightly increased, with the PE-TTM for packaging printing, home furnishing, paper, and entertainment products at 41.74, 29.68, 32.38, and 48.91 respectively [78] Investment Recommendations - For the home furnishing sector, it is recommended to focus on Oppein and Songlin Technology; for the packaging sector, attention should be on Aorijin, Yutong Technology, and Xianggang Technology; in the toy sector, focus on Pop Mart; in the paper sector, consider Jiulong Paper and Hengfeng Paper; additionally, the expansion of HNB is expected to drive high prosperity in the tobacco-related industry chain, recommending attention to China Tobacco Hong Kong [81]

Investment Rating - The investment rating for Smoore International is maintained as "Buy-A" with a target price of HKD 16.80 [6][4]. Core Insights - Smoore International has demonstrated strong confidence in its long-term value through significant share buybacks, totaling nearly HKD 200 million over two days [2]. - The company reported record revenue of approximately RMB 4.197 billion for Q3 2025, reflecting a year-on-year growth of 27.2%, driven by the successful launch of new heated not-burn (HNB) products in major global markets [3]. - The company is positioned to benefit from stricter global regulations on non-compliant products, enhancing its status as a compliant leader in the industry [4]. Financial Summary - Revenue projections for Smoore International from 2025 to 2027 are RMB 141.08 billion, RMB 167.17 billion, and RMB 198.67 billion, representing year-on-year growth rates of 19.57%, 18.50%, and 18.84% respectively [4]. - Net profit estimates for the same period are RMB 10.43 billion, RMB 19.31 billion, and RMB 27.26 billion, with growth rates of -19.93%, 85.12%, and 41.14% respectively [4]. - The company’s price-to-earnings (PE) ratios are projected to be 63.16x, 34.12x, and 24.17x for 2025, 2026, and 2027 respectively [4].

Group 1 - The core viewpoint of the report is that Smoore International (06969) maintains a "Buy" investment rating due to its leadership in the global electronic vaporization market, ongoing R&D efforts, and strong management confidence reflected in recent share buybacks [1] - The company has conducted significant share repurchases, spending nearly HKD 200 million over two days, which indicates long-term confidence from management regarding the company's value and future business growth [1] - The projected revenue for Smoore International from 2025 to 2027 is estimated to be RMB 14.108 billion, RMB 16.717 billion, and RMB 19.867 billion, representing year-on-year growth rates of 19.57%, 18.50%, and 18.84% respectively [1] Group 2 - In Q3 2025, the company achieved record revenue of approximately RMB 4.197 billion, a year-on-year increase of 27.2%, primarily driven by the successful launch of heated not-burn (HNB) products by strategic clients in major global markets [2] - The tightening of global regulations has accelerated the exit of non-compliant products, allowing the company, as a compliant leader, to fully benefit from policy advantages, resulting in steady growth in its electronic vaporization business [2] - The adjusted net profit for Q3 was approximately RMB 444 million, reflecting a year-on-year growth of 4.0%, with excellent cost control as the growth rate of expenses was lower than that of revenue [2]

Core Viewpoint - Guotou Securities maintains a "Buy" rating for Smoore International (06969), highlighting its leadership in the global electronic vaporization market and its commitment to R&D and technology innovation. The company is expected to benefit from increased regulatory scrutiny on non-compliant products and ongoing business expansion, with significant share buybacks reflecting long-term confidence in its growth potential [1][8]. Group 1: Share Buybacks - The company executed two significant share buybacks on December 11 and 12, spending nearly HKD 200 million. On December 11, it repurchased 8.14 million shares at an average price of HKD 12.26 per share, costing HKD 99.77 million. On December 12, it repurchased 7.99 million shares at an average price of HKD 12.48 per share, costing HKD 99.76 million. The proportion of shares held by the trustee increased from 1.2853% to 1.5457%, indicating management's long-term confidence in the company's value and future growth [2][8]. Group 2: Financial Performance - In Q3 2025, the company achieved a record revenue of approximately RMB 4.197 billion, representing a year-on-year growth of 27.2%. This strong performance was primarily driven by the successful launch of heated not-burn (HNB) products by strategic clients in major global markets. The tightening global regulations accelerated the exit of non-compliant products, allowing the company to fully benefit from policy advantages as a compliant leader. The flagship new products contributed to an increase in the share of its proprietary brand business. Adjusted net profit for Q3 was approximately RMB 444 million, up 4.0% year-on-year, with expense growth below revenue growth, indicating excellent cost control [3][9]. Group 3: Revenue Projections - Guotou Securities projects Smoore International's revenue for 2025-2027 to be RMB 14.108 billion, RMB 16.717 billion, and RMB 19.867 billion, reflecting year-on-year growth rates of 19.57%, 18.50%, and 18.84% respectively. The company is assigned a target price of HKD 16.80 for 2026, based on a price-to-earnings ratio of 48x [1][8].